NCT03571321
|
Phase I |
Pegaspargase
Methotrexate
Cytarabine
Mercaptopurine
Thioguanine
Ruxolitinib
Cyclophosphamide
Dexamethasone
Vincristine
Rituximab
Doxorubicin
|
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia |
Not yet recruiting |
NCT02883049
|
Phase III |
Dasatinib
Dexamethasone + Doxorubicin
Prednisone
Vincristine
Thioguanine
Cytarabine
Mercaptopurine
Leucovorin
Methotrexate
Pegaspargase
Etoposide
Clofarabine
|
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations |
Recruiting |
NCT00549848
|
Phase III |
Vincristine + Pegaspargase + Daunorubicin
Cytarabine
Mercaptopurine
Thioguanine
Clofarabine + Etoposide + Cyclophosphamide
Methotrexate
Dasatinib
Doxorubicin
Dexamethasone
|
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia |
Active, not recruiting |
NCT02112916
|
Phase III |
Cyclophosphamide
Vincristine
Ifosfamide
Pegaspargase
Methotrexate
Cytarabine
Mercaptopurine
Thioguanine
Leucovorin
Daunorubicin
Dexamethasone
Bortezomib
Etoposide
Doxorubicin
|
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma |
Suspended |
NCT00550992
|
Phase I |
Busulfan
Melphalan
Mercaptopurine
Mitoxantrone + Etoposide + Cytarabine
Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase
Thioguanine
Cyclosporine
anti-thymocyte globulin
Daunorubicin
Leucovorin
|
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia |
Unknown status |
NCT02551718
|
Phase I |
Bosutinib
Irinotecan
romidepsin
Busulfan
Melphalan
Nilotinib
Crizotinib
Cytarabine
Mitoxantrone
Dasatinib
Pazopanib
Paclitaxel
Clofarabine
Hydroxyurea
Tretinoin
Carfilzomib
Nelarabine
Bexarotene
Pentostatin
Everolimus
Cabozantinib
Mercaptopurine
Methotrexate
Cladribine
Thioguanine
Daunorubicin
Ponatinib
Etoposide
Afatinib
Gefitinib
Gemcitabine
Regorafenib
Arsenic trioxide
Trametinib
Imatinib
Erlotinib
Dabrafenib
Decitabine
Axitinib
Azacitidine
Ruxolitinib
Fludarabine
Lapatinib
Ceritinib
Sirolimus
Sorafenib
Lomustine
Sunitinib
Cabazitaxel
Temsirolimus
Topotecan
Bortezomib
Pralatrexate
|
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia |
Recruiting |
NCT03007147
|
Phase III |
Pegaspargase
Methotrexate
Leucovorin
Cytarabine
Mercaptopurine
Thioguanine
Vincristine
Cyclophosphamide
Imatinib
Ifosfamide
dexrazoxane
Daunorubicin
Dexamethasone
Methylprednisolone
Etoposide
Prednisolone
Doxorubicin
|
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
Recruiting |
NCT03150693
|
Phase III |
Rituximab
Doxorubicin
Mercaptopurine
Methotrexate
Cyclophosphamide + Cytarabine
Thioguanine
Allopurinol
Daunorubicin
Dexamethasone
Vincristine
inotuzumab ozogamicin
|
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia |
Recruiting |
NCT02788201
|
Phase II |
Erlotinib
Thiotepa
Imatinib
Dacarbazine
Arsenic trioxide
Idarubicin
Mitomycin C
Thioguanine
Mercaptopurine
Methotrexate
Cladribine
epirubicin
Gemcitabine
Doxorubicin
Bleomycin
Etoposide
Gefitinib
Daunorubicin
Lomustine
Sorafenib
Sunitinib
Ifosfamide
Asparaginase
Ixabepilone
Abiraterone
Azacitidine
Ruxolitinib
Decitabine
Axitinib
Estramustine
Floxuridine
Lapatinib
Carmustine
Fludarabine
Nilotinib
Cisplatin
Vismodegib
Vandetanib
Melphalan
Busulfan
Carboplatin
Toremifine
Crizotinib
Dactinomycin
Temsirolimus
Vorinostat
romidepsin
Fluorouracil
Irinotecan
Bortezomib
Tamoxifen
Topotecan
Chlorambucil
Pentostatin
Eribulin
Carfilzomib
Vemurafenib
Hydroxyurea
Exemestane
Vincristine
Dasatinib
Mitoxantrone
Vinblastine
Cytarabine
Tretinoin
Clofarabine
Teniposide
Docetaxel
Pazopanib
Oxaliplatin
Streptozocin
Paclitaxel
Bendamustine
Mechlorethamine
Mitotane
|
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma |
Recruiting |
NCT02521493
|
Phase III |
Etoposide
Thioguanine
Cytarabine
Asparaginase Erwinia chrysanthemi
mitoxantrone hydrochloride
Daunorubicin
Asparaginase
|
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome |
Recruiting |